jRCT2031210316已完成不适用
A Phase III Confirmatory Study of K-237-Multi-regional, Multi-center, Placebo Controlled, Randomized, Double Blind, Parallel Group Controlled Trial in Patients with mild COVID-19
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,000
- 主要终点
- Time from the start of study drug administration to clinical symptoms improvement
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Double Blind
入排标准
- 年龄范围
- 12age old over 至 No limit（—）
- 性别
- All
入选标准
- •Patients who meet all of the following criteria will be eligible for this study.
- •(1) Males and females who are 12 years of age or older at the time of obtaining consent
- •(2) Patients who are confirmed positive for SARS-CoV-2 by antigen test or RT-PCR test using specimens (nasopharynx, nasal cavity, oropharynx, or saliva) collected within 120 hours prior to obtaining consent.
- •(3) Patients who have fevers (>= 37.5 degrees Celsius) and/or at least one of the following symptoms of Score 2 or higher at a screening test:Myalgia, sore throat, diarrhea, nausea, vomiting, cough, and shortness of breath.
- •(4) Patients with a room air oxygen saturation (SpO2) of 96% or higher at the time of the screening test.
排除标准
- •Subjects who meet any one of the following criteria will be excluded from this study.
- •(1) Patients who have had symptoms caused by COVID-19 for more than 6 days on the day of initiation of investigational drug administration (Day 1) with the day of onset of symptoms as Day
- •(2) Patients who need to receive concomitant therapy or administration of prohibited drugs during the study period
- •(3) Patients who have taken or received drugs that have or may have antiviral activity against SARS-CoV-2 within 2 weeks prior to the start of study drug administration
- •(4) Patients with suspected complications of infectious diseases other than COVID-19
- •(5) Persons whose weight at the time of the screening test falls into the following categories (The first decimal place of the weight shall be rounded off.)
- •Those who are 18 years of age or older at the time of consent and weigh less than 25 kg or more than 127 kg
- •Those who are between 12 and 18 years of age and weigh less than 40 kg or 127 kg or more at the time of obtaining consent.
- •(6) Patients undergoing dialysis treatment
- •(7) Patients wno have severe liver dysfunction (hepatic dysfunction, hepatic fibrosis, etc.)
- •(8) Patients wno have complications of poorly controlled hypertension (systolic blood pressure (SBP) of 180 mmHg or more or diastolic blood pressure (DBP) of 110 mmHg or more)
- •(9) Patients requiring oxygen therapy
- •(10) Patients wno have complications of methemoglobinemia or other diseases that may cause measurement errors in the pulse oximeter
结局指标
主要结局
Time from the start of study drug administration to clinical symptoms improvement
时间窗: 168 hours
Time from the start of study drug administration to 168 hours before the clinical symptoms started to improve
次要结局
未报告次要终点
研究者
相似试验
进行中（未招募）
3 期
A Phase III Confirmatory Study of K-237COVID-19JPRN-jRCT2031210316Tanigawa Ryohei1,000
已完成
3 期
A Phase III Confirmatory Study of K-877 Extended Release TabletDyslipidemiaJPRN-jRCT2051200128Tanigawa Ryohei345
招募中
3 期
A Phase III Confirmatory Study of K-877 (Pemafibrate) in Patients with Hypercholesterolemia and Statin IntoleranceHypercholesterolemiaJPRN-jRCT2051230055Tanigawa Ryohei60
已完成
不适用
A Phase III Confirmatory Study of K-877 (Pemafibrate) in Patients with Hypercholesterolemia and Statin IntoleranceHypercholesterolemiajRCT2051230055Kowa Company, Ltd.60
未知
3 期
Comparative confirmatory study of K-877DyslipidemiaJPRN-jRCT2080222569Kowa Co., Ltd.225